Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thalidomide
Drug ID BADD_D02192
Description A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Indications and Usage For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Marketing Status Prescription
ATC Code L04AX02
DrugBank ID DB01041
KEGG ID D00754
MeSH ID D013792
PubChem ID 5426
TTD Drug ID D0U7GK
NDC Product Code 59572-205; 59572-210; 59572-220; 59572-215; 69988-0052; 63818-0424; 17337-0301; 68554-0011
Synonyms Thalidomide | Sedoval | Thalomid
Chemical Information
Molecular Formula C13H10N2O4
CAS Registry Number 50-35-1
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Deep vein thrombosisThrombomodulinP07204T0858315235749; 7878634
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cyanosis22.02.02.007; 02.01.02.002; 24.03.01.007--
Cyst16.02.02.002; 08.03.05.0010.001158%Not Available
Cystitis20.03.02.002; 11.01.14.001--
Deafness04.02.01.0010.004053%Not Available
Death08.04.01.0010.065099%
Decubitus ulcer23.03.11.0060.001737%Not Available
Dehydration14.05.05.0010.011001%
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.0010.005211%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.000453%Not Available
Demyelination17.16.02.001--Not Available
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.001158%
Diabetes mellitus05.06.01.001; 14.06.01.0010.007527%Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.001158%Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Disability26.01.01.003--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
Diverticulitis11.01.07.003; 07.10.02.0010.002895%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.039371%
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.0050.001158%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug interaction08.06.03.001--Not Available
Dry eye06.08.02.0010.002316%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 24 Pages